SITM Soars 28.8% as EPS Revisions Fuel Broad-Based Rally
Five stocks detected by our EPS revision screener delivered outsized gains, led by SiTime (SITM) up 28.8% to $457.05 after analysts raised its next-year EPS growth estimate from 32.4% to 43.3%. Optimum Communications (OPTU) and Vericel (VCEL) each gained over 28% as earnings beats and restructuring catalysts confirmed the revisions, while INVO Fertility (IVF) and Wolfspeed (WOLF) rounded out the top performers with gains exceeding 28% apiece.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| OPTU | Communication Services | 2026-11-05 | N/A | +40.4% |
| SITM | Technology | 2026-11-05 | +10.9pp | +28.8% |
| IVF | Healthcare | 2026-11-02 | N/A | +28.4% |
| VCEL | Healthcare | 2026-11-04 | N/A | +28.4% |
| WOLF | Technology | 2026-11-05 | N/A | +28.3% |
Why did OPTU stock jump in November 2026?
OPTU jumped 40.4% (from $0.57 to $0.80) after its next-year EPS growth estimate of 86.9% was flagged by our screener on November 5, 2026.
The catalyst was the company's announcement that it would file its Q3 2026 Form 10-Q on November 6 without hosting an earnings call, as it pursues a comprehensive consensual restructuring of its capital structure. That operational update reinforced the high-growth EPS forecast, which reflects cost cuts and subscriber gains across its 4.2 million broadband customers in 21 states. The stock's low float and penny-stock status amplified the move, with the screener catching the revision before the broader market fully priced in the restructuring narrative.
OPTU EPS revision history → · Screener snapshot from 2026-11-05 →
FAQ: OPTU
Why did OPTU stock jump in November 2026?
OPTU jumped 40.4% to $0.80 after our screener detected an 86.9% next-year EPS growth estimate on November 5, 2026, supported by the company's Q3 filing and restructuring efforts.
What caused OPTU's surge?
The surge was driven by a high EPS growth forecast and the company's announcement of a consensual capital restructuring, which investors viewed as a path to profitability despite no earnings call.
Is OPTU a buy after its 40% rally?
With an 86.9% next-year EPS growth estimate and a restructuring underway, OPTU carries high risk but offers potential upside if the capital plan succeeds; the stock remains speculative at $0.80.
Why did SITM stock jump in November 2026?
SITM jumped 28.8% (from $355.00 to $457.05) after analysts revised its next-year EPS growth estimate from 32.4% to 43.3% on November 5, 2026.
The revision followed a blockbuster Q3 report on November 4, with non-GAAP EPS of $4.01 beating the $3.41 consensus and revenue surging 257% year over year to $298.7 million. Seaport Global upgraded the stock to Buy from Neutral with a $425 price target on November 6, citing an attractive entry point after a 50% sell-off from September peaks. The upgrade and estimate revision confirmed the AI infrastructure demand story, pushing shares past the target as the market re-rated the precision timing specialist.
SITM EPS revision history → · Screener snapshot from 2026-11-05 →
FAQ: SITM
Why did SITM stock jump in November 2026?
SITM jumped 28.8% to $457.05 after analysts raised its next-year EPS growth estimate to 43.3% on November 5, 2026, following a Q3 earnings beat and a Seaport upgrade to Buy.
What caused SITM's surge?
The surge was driven by a 10.9 percentage point upward revision in EPS growth estimates, a Q3 revenue beat of $298.7 million, and a Buy upgrade from Seaport Global with a $425 target.
Is SITM a buy after its 28% rally?
Seaport upgraded SITM to Buy with a $425 target on November 6, but the stock has already surpassed that level at $457.05, suggesting the market is pricing in further growth from AI infrastructure demand.
Why did IVF stock jump in November 2026?
IVF jumped 28.4% (from $1.83 to $2.35) after our screener flagged a next-year EPS growth estimate of 98.6% on November 2, 2026.
No company-specific news drove the move; instead, the revision reflected improving sector sentiment toward fertility treatments as healthcare providers expand coverage and demand rebounds. The micro-cap stock's thin trading volume amplified the price impact of the estimate change, which signaled a path to near-doubling earnings. Investors rotating into high-growth healthcare names ahead of year-end positioned IVF as a speculative play on the fertility market's recovery.
IVF EPS revision history → · Screener snapshot from 2026-11-02 →
FAQ: IVF
Why did IVF stock jump in November 2026?
IVF jumped 28.4% to $2.35 after our screener detected a 98.6% next-year EPS growth estimate on November 2, 2026, with no specific news but supported by sector momentum.
What caused IVF's surge?
The surge was driven by the high EPS growth forecast, which reflected improving fertility treatment demand and coverage expansion, amplified by the stock's low liquidity.
Is IVF a buy after its 28% rally?
IVF's 98.6% EPS growth estimate offers upside, but the micro-cap stock is highly speculative with no recent earnings news; investors should weigh the risk of low liquidity and sector volatility.
Why did VCEL stock jump in November 2026?
VCEL jumped 28.4% (from $45.48 to $58.39) after our screener detected a 61.9% next-year EPS growth estimate on November 4, 2026.
The revision was confirmed by a Q3 beat-and-raise on November 5, with earnings of $0.27 per share versus a $0.02 consensus and revenue up 26% to $85.4 million. Management raised full-year revenue guidance to $344-$346 million and lifted its adjusted EBITDA margin target to 28%, marking the third consecutive quarterly raise. The strong MACI sports medicine franchise and improving burn care results drove the re-rating, as the market priced in durable growth.
VCEL EPS revision history → · Screener snapshot from 2026-11-04 →
FAQ: VCEL
Why did VCEL stock jump in November 2026?
VCEL jumped 28.4% to $58.39 after our screener flagged a 61.9% next-year EPS growth estimate on November 4, 2026, followed by a Q3 beat-and-raise on November 5.
What caused VCEL's surge?
The surge followed a Q3 earnings beat of $0.27 per share versus a $0.02 consensus, a 26% revenue increase to $85.4 million, and the third consecutive guidance raise for 2026.
Is VCEL a buy after its 28% rally?
With a 61.9% EPS growth estimate and a strong beat-and-raise quarter, VCEL shows durable momentum, but the stock's 28% gain may already reflect near-term optimism; watch for sustained MACI growth.
Why did WOLF stock jump in November 2026?
WOLF jumped 28.3% (from $20.36 to $26.12) after our screener flagged a 27.2% next-year EPS growth estimate on November 5, 2026.
The revision followed a fiscal Q1 report on November 4 that, despite a narrow EPS miss, featured a higher revenue guide, a near-breakeven gross margin outlook, and a conditional $1.5 billion government loan to replace expensive debt. The loan and margin improvement signaled a turnaround from Chapter 11, with the share count reduced from 156 million to 55 million. Investors looked past the GAAP loss to the improving sequential trends, driving the stock higher as the estimate revision captured the path to profitability.
WOLF EPS revision history → · Screener snapshot from 2026-11-05 →
FAQ: WOLF
Why did WOLF stock jump in November 2026?
WOLF jumped 28.3% to $26.12 after our screener detected a 27.2% next-year EPS growth estimate on November 5, 2026, supported by a higher revenue guide and a $1.5 billion conditional loan.
What caused WOLF's surge?
The surge was driven by the EPS revision and management's guidance for near-breakeven gross margins, plus a $1.5 billion government loan that would replace costly debt and aid the post-bankruptcy turnaround.
Is WOLF a buy after its 28% rally?
WOLF's 27.2% EPS growth estimate and improving margins offer upside, but cash burn and a shrinking product line remain risks; the $1.5 billion loan is conditional and the stock is volatile post-restructuring.
The breadth of today's EPS-driven gains—spanning telecom, semiconductors, healthcare, and renewable energy—signals that investors are aggressively rewarding upward estimate revisions despite mixed earnings headlines. SITM's 28.8% move on a 10.9pp revision and VCEL's beat-and-raise suggest the market is in a momentum-driven phase where forward growth expectations outweigh near-term execution risks.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →